Novo Nordisk Tumbles in 'Worst Case Scenario': Next-Gen Weight Loss Drug Underperforms

Novo Nordisk AS (NYSE:NVO) , once the darling of the pharmaceutical world, tumbled Monday as investors reacted to what analysts are calling a “worst-case scenario.” NVO stock is tumbling. See the chart and price action here. Shares of Novo Nordisk stock plunged over 16% in morning trading, hitting a new 52-week low following disappointing results from the REDEFINE 4 Phase 3 clinical trial. This latest blow brings the stock’s one month decline to 36%.The Data Gap: CagriSema vs. TirzepatideThe 84-week trial i ...